GBM AGILE also assesses paxalisib in recurrent GBM.
There is no prior data on paxalisib in this sub-population.
I also take it as a good sign that the results for paxalisib have not been published.
Paxalisib was arguably easier to administer as an oral than an iv drug like VAL-083 - meaning that patient recruitment should have been faster.
But VAL-083 was also assessed in methylated patients.
A big question for me the split between newly-diagnosed vs recurrent cases in the paxalisib arm.
John Friend confirmed in the latest IR video that GBM AGILE results for paxalisib are still on track for publication in 2023.
- Forums
- ASX - By Stock
- KZA
- Unravelling glioblastoma’s secrets and harnessing two decades of progress
Unravelling glioblastoma’s secrets and harnessing two decades of progress, page-5
-
- There are more pages in this discussion • 5 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add KZA (ASX) to my watchlist
Currently unlisted public company.
The Watchlist
CCO
THE CALMER CO INTERNATIONAL LIMITED
Anthony Noble, MD & CEO
Anthony Noble
MD & CEO
Previous Video
Next Video
SPONSORED BY The Market Online